Nafarelin Research Dosage: Published Protocol Reference
Nafarelin dosage references vary by route and study context. The database lists Intranasal spray: 200 mcg per spray, Endometriosis: 1 spray in one nostril AM, 1 spray in other nostril PM (400 mcg/day) and Intranasal spray: 200 mcg per spray, CPP: 2 sprays each nostril AM and PM (1600 mcg/day). These are research-context references, not a universal protocol.
Direct Answer
Nafarelin (Synarel) is FDA-approved for endometriosis and central precocious puberty via intranasal delivery - an unusual route for a peptide drug that demonstrates its unique pharmaceutical development. Phase 3 evidence for both indications is solid. For GnRH agonist research requiring intranasal administration, nafarelin is the validated option.
- Evidence grade
- Level A
- Research status
- FDA Approved
- Category
- Sexual Health
- Best for
- Endometriosis treatment, central precocious puberty, intranasal GnRH agonist research
Research Dosage References
- <strong>Intranasal spray</strong> - 200 mcg per spray - Endometriosis: 1 spray in one nostril AM, 1 spray in other nostril PM (400 mcg/day) - Treatment duration for endometriosis typically 6 months. Sneezing or rhinitis may reduce absorption - avoid nasal decongestants for 30 minutes after dosing.
- <strong>Intranasal spray</strong> - 200 mcg per spray - CPP: 2 sprays each nostril AM and PM (1600 mcg/day) - Higher doses used in central precocious puberty. May increase to 1800 mcg/day if suppression inadequate.
Half-Life
~3 hours.
Evidence Limits
Dosage entries are compiled from labels, published studies, and research-context references where available. For Nafarelin, the evidence grade is Level A, and the current research status is FDA Approved.
Safety Signals
- Nasal congestion or use of nasal decongestant sprays may reduce absorption
- Bone density monitoring recommended for treatment >6 months
- Not for use in pregnancy (Category X)
- Add-back hormonal therapy recommended for endometriosis treatment beyond 6 months
Evidence Snapshot
| Evidence grade | Level A |
|---|---|
| Research status | FDA Approved |
| Best supported outcomes | Endometriosis Pain Relief (Level A), Central Precocious Puberty Treatment (Level A), and Uterine Fibroid Reduction (Level B) |
| Primary citation count | 3 |
| Last reviewed | 2026-06-02 |
Related Guides
How to Cite This Page
ExaminePeptides. "Nafarelin Research Dosage: Published Protocol Reference." Last reviewed 2026-06-02. https://examinepeptides.com/answers/nafarelin-research-dosage/
This static answer page is built for fast indexing and direct citation. It summarizes the matching full evidence review and links back to primary sources where the source database includes them.